Triglide Side Effects
Generic name: fenofibrate
Note: This document contains side effect information about fenofibrate. Some of the dosage forms listed on this page may not apply to the brand name Triglide.
Some side effects of Triglide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to fenofibrate: oral capsule, oral tablet
Along with its needed effects, fenofibrate (the active ingredient contained in Triglide) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fenofibrate:Less common
- Chills or fever
- hives or skin rash
- muscle aches and pains
- nausea or vomiting
- Chronic indigestion
- dark urine
- muscle cramps, pain, stiffness, swelling, or weakness
- troubled breathing
- unusual bleeding or bruising
- unusual tiredness
- yellow eyes or skin
- bloody urine
- decreased frequency or amount of urine
- lower back or side pain
- pains in the stomach, side, or abdomen, possibly radiating to the back
- swelling of the face, fingers, or lower legs
- swollen joints
- upper right abdominal or stomach pain
Some side effects of fenofibrate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Runny nose
- stuffy nose
- Back pain
- eye irritation
- increased sensitivity of the skin to sunlight
- Lack or loss of strength
For Healthcare Professionals
Applies to fenofibrate: oral capsule, oral tablet
General total body symptoms have included asthenia/fatigue or flu-like symptoms (5%) and infection (18%). During clinical studies, 6% of patients discontinued fenofibrate (the active ingredient contained in Triglide) because of drug-related adverse effects. The most common reason for discontinuation of fenofibrate was skin rash in 2% of patients.
Body as a whole effects probably related to fenofibrate or where causality has not yet been established include weight loss and fever.
In clinical studies, 6% of patients receiving 134 mg to 200 mg fenofibrate (the active ingredient contained in Triglide) daily experienced transaminase levels greater than 3 times the upper limits of normal. No such incidences occurred in patients receiving dosages of 34 mg to 67 mg daily. Hepatotoxicity can occur following weeks or years of therapy and is dose related. Cirrhosis associated with chronic active hepatitis has been reported.
Hepatic side effects have included significant increases in serum transaminase levels.
Patients should be instructed to report symptoms of muscle pain, weakness, or tenderness. If such symptoms develop, creatine kinase should be measured, and, if elevated, fenofibrate (the active ingredient contained in Triglide) should be discontinued.
Gemfibrozil is associated with a higher incidence of myotoxicity (i.e., rhabdomyolysis) than fenofibrate when used in combination with any HMG CoA reductase inhibitor (statin). Fenofibrate is primarily metabolized by glucuronidation, whereas gemfibrozil undergoes extensive oxidative metabolism which results in higher plasma levels of statins. This pharmacokinetic difference may account for the differences in the rates of myotoxicity.
A patient with auto-immune thyroiditis induced hypothyroidism developed acute renal failure secondary to simvastatin/fenofibrate combination therapy induced rhabdomyolysis. Following discontinuation of simvastatin/fenofibrate therapy and thyroid replacement, symptoms (i.e., muscle pain, oliguria) resolved and renal function returned to normal within 14 days.
Musculoskeletal side effects have included arthralgias (3%). In addition, the use of fibrate derivatives, including fenofibrate occasionally has been associated with myositis. Rhabdomyolysis has occurred rarely and generally in association with impaired renal function. Myopathy should be considered in the presence of symptoms of diffuse myalgias, muscle tenderness or weakness, and/or significant increase in serum creatine kinase. Combination therapy with HMG-CoA reductase inhibitors may increase the potential for myositis. Elevations in serum creatinine have also been associated with fenofibrate therapy.
Gastrointestinal side effects included dyspepsia (5%), nausea/vomiting (4%), flatulence, abdominal pain, constipation, or diarrhea (3%), and eructation (1%). In addition, an increased incidence of gallbladder disease/surgeries and pancreatitis occurred during clinical studies. Fibrate derivatives, including fenofibrate (the active ingredient contained in Triglide) may increase cholesterol excretion into bile and result in cholelithiasis.
Gastrointestinal side effects having occurred during fenofibrate therapy where causality has not yet been established have included hematemesis.
Dermatologic side effects have included pruritus (3%) and rash (6%). During clinical studies, 2% of patients discontinued fenofibrate (the active ingredient contained in Triglide) therapy because of rashes.
Dermatologic side effects possibly related to fenofibrate or where causality has not yet been established have included: photosensitivity, eczema, lupus-like syndrome, ichthyosis, telangiectasis, and alopecia.
Renal side effects have included acute renal failure. The accumulation of fenofibric acid in the presence of preexisting renal dysfunction causes an increase in levels of fenofibric acid, the main metabolite of fenofibrate (the active ingredient contained in Triglide) Renal side effects of fenofibric acid accumulation include acute renal failure associated with myositis and rhabdomyolysis.
Cardiovascular effects which have occurred during fenofibrate (the active ingredient contained in Triglide) therapy where causality has not yet been established include facial and peripheral edema, angina, palpitations, tachycardia, migraine and epistaxis.
Cardiovascular side effects have included arrhythmia (1%) and pulmonary embolus (PE).
Nervous system side effects have included decreased libido (2%) and insomnia (1%).
Nervous system effects probably related to fenofibrate or where causality has not yet been established include dry mouth, vertigo, anxiety, sleep disorders, and confusion.
Respiratory effects probably related to fenofibrate (the active ingredient contained in Triglide) or where causality has not yet been established include allergic pulmonary alveolitis and congestion.
Respiratory side effects have included cough or sinusitis (1%) and rhinitis (4%).
Ocular side effects have included eye irritation (2%), eye floaters, blurred vision, or conjunctivitis (1%).
Otic side effects have included earache (1%).
Genitourinary side effects have included polyuria or vaginitis (1%).
Genitourinary effects occurring during fenofibrate where causality has not yet been established have included decreased male fertility and renal lithiasis.
Hypersensitivity side effects have included severe skin rashes (requiring hospitalization and steroid therapy), urticaria and less severe rashes.
Hematologic side effects have included mild to moderate decreases in hemoglobin and hematocrit and white blood cells, rare incidences of thrombocytopenia and agranulocytosis, and deep vein thrombosis (DVT).
Oncologic effects of tumor growth in rodents have been associated with many lipid-lowering drugs. Fenofibrate (the active ingredient contained in Triglide) has been associated with liver, pancreatic and testicular tumors in rats. Long-term clinical trials are needed to define the risk of cancer in humans.
Endocrine side effects include at least one case of fenofibrate-induced gynecomastia that resolved following discontinuation and recurred upon rechallenge.
More Triglide resources
- Triglide Advanced Consumer (Micromedex) - Includes Dosage Information
- Triglide Prescribing Information (FDA)
- Fenofibrate Monograph (AHFS DI)
- Fenofibrate Prescribing Information (FDA)
- Fenofibrate Professional Patient Advice (Wolters Kluwer)
- Antara Prescribing Information (FDA)
- Antara MedFacts Consumer Leaflet (Wolters Kluwer)
- Fenoglide Prescribing Information (FDA)
- Lipofen Prescribing Information (FDA)
- Lipofen MedFacts Consumer Leaflet (Wolters Kluwer)
- Lofibra Prescribing Information (FDA)
- Tricor Consumer Overview
- Tricor Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.